KalshiCheck availabilityKYC required2% feeVerified resolution dataRoughly calibratedCurrent implied probabilityYes 98%
Market quality
42 / 100
Low quality24h Volume
$0
Liquidity
$1K
Low liquidityBid / Ask
79.0% / 86.0%
Spread
7.0 pt
Wide spreadMarket data
Updated 13 minutes ago
Jun 17, 26, 9:00 PMJan 1, 27, 4:59 AM
Trends
Paper funds only — no real moneyNot financial advice
Selected outcome
Yes98%
Volume trend
$812Jul 310d of dataJul 26
Related Markets
Hantavirus pandemic in 2026?
$105.4KYes: 3%
POLYMARKET
POLYMARKET
# of views of MrBeast video day 3?
$8.7K26-27M: 89%POLYMARKET
POLYMARKET
New pandemic in 2026?
$5.8KYes: 9%POLYMARKET
POLYMARKET
Measles cases in 2026?
$2.8KAbove 3000: 94%KALSHI
KALSHI
Pandemic in 2026?
$2.3KYes: 5%KALSHI
KALSHI
Cyclosporiasis cases reported in the US in 2026?
$1.3KAbove 20k: 34%KALSHI
KALSHIActive in these topics
Rules
If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
- Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
- In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.